Rydapt (midostaurin) is a small molecule pharmaceutical. Midostaurin was first approved as Rydapt on 2017-04-28. It is used to treat hematologic neoplasms, myeloid leukemia acute, and systemic mastocytosis in the USA. It has been approved in Europe to treat mastocytosis and myeloid leukemia acute. The pharmaceutical is active against receptor-type tyrosine-protein kinase FLT3. In addition, it is known to target dual specificity tyrosine-phosphorylation-regulated kinase 1A. Rydapt's patents are valid until 2030-12-02 (FDA).
|Indication||hematologic neoplasms, mastocytosis, myeloid leukemia acute, systemic mastocytosis|